Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2017, Article ID 4296474, 4 pages
https://doi.org/10.1155/2017/4296474
Case Report

Severe Cholestasis and Bile Cast Nephropathy Induced by Anabolic Steroids Successfully Treated with Plasma Exchange

1Family Medicine Division, Lebanese American University Medical Center, Beirut, Lebanon
2Internal Medicine Division, Morristown Medical Center, Morristown, NJ, USA
3Laboratory Medicine Division, Lebanese American University Medical Center, Beirut, Lebanon
4Gastroenterology Division, Lebanese American University Medical Center, Beirut, Lebanon

Correspondence should be addressed to Antoine Ferzli; moc.hrcmual@ilzref.eniotna

Received 7 October 2017; Accepted 5 November 2017; Published 17 December 2017

Academic Editor: William B. Silverman

Copyright © 2017 Christelle El Khoury et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Solimini, M. Rotolo, L. Mastrobattista et al., “Hepatotoxicity associated with illicit use of anabolic androgenic steroids in doping,” European Reviews for Medical and Pharmacological Sciences, vol. 21, no. 1, pp. 7–16, 2017. View at Google Scholar
  2. A. E. Field, K. R. Sonneville, R. D. Crosby et al., “Prospective associations of concerns about physique and the development of obesity, binge drinking, and drug use among adolescent boys and young adult men,” Journal of the American Medical Association Pediatrics, vol. 168, no. 1, pp. 34–39, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Neri, S. Bello, A. Bonsignore et al., “Anabolic androgenic steroids abuse and liver toxicity,” Mini Reviews in Medicinal Chemistry, vol. 11, no. 5, pp. 430–437, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Modlinski and K. B. Fields, “The effect of anabolic steroids on the gastrointestinal system, kidneys, and adrenal glands,” Current Sports Medicine Reports, vol. 5, no. 2, pp. 104–109, 2006. View at Publisher · View at Google Scholar
  5. A. Flores, R. Nustas, H.-L. Nguyen, and R. S. Rahimi, “Severe cholestasis and bile acid nephropathy from anabolic steroids successfully treated with plasmapheresis,” American College of Gastroenterology Case Reports Journal, vol. 3, no. 2, pp. 133–135, 2016. View at Publisher · View at Google Scholar
  6. L. Socas, M. Zumbado, O. Perez-Luzardo et al., “Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature,” British Journal of Sports Medicine, vol. 39, no. 5, p. e27, 2005. View at Publisher · View at Google Scholar
  7. M. Keklik, S. Sivgin, L. Kaynar et al., “Treatment with plasma exchange may serve beneficial effect in patients with severe hyperbilirubinemia: a single center experience,” Transfusion and Apheresis Science, vol. 48, no. 3, pp. 323–326, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Reents, Sport and Exercise Pharmacology, Human Kinetics 1, Champaign, IL, USA, 2000.
  9. C. Maravelias, A. Dona, M. Stefanidou, and C. Spiliopoulou, “Adverse effects of anabolic steroids in athletes: a constant threat,” Toxicology Letters, vol. 158, no. 3, pp. 167–175, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. E. S. Björnsson and J. H. Hoofnagle, “Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports,” Hepatology, vol. 63, no. 2, pp. 590–603, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Büttner and D. Thieme, “Side effects of anabolic androgenic steroids: pathological findings and structure–activity relationships,” in Doping in Sports: Biochemical Principles, Effects and Analysis, pp. 459–484, Springer, New York, NY, USA, 2010. View at Google Scholar
  12. N. T. Shahidi, “A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids,” Clinical Therapeutics, vol. 23, no. 9, pp. 1355–1390, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. E. M. Yoshida, M. A. Karim, J. F. Shaikh, J. G. Soos, and S. R. Erb, “At what price, glory? Severe cholestasis and acute renal failure in an athlete abusing stanozolol,” Canadian Medical Association Journal, vol. 151, no. 6, pp. 791–793, 1994. View at Google Scholar
  14. G. B. Odell, “The distribution of bilirubin between albumin and mitochondria,” Journal of Pediatrics, vol. 68, no. 2, pp. 164–180, 1966. View at Publisher · View at Google Scholar
  15. C. M. van Slambrouck, F. Salem, S. M. Meehan, and A. Chang, “Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction,” Kidney International, vol. 84, no. 1, pp. 192–197, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. R. L. Luciano, E. Castano, G. Moeckel, and M. A. Perazella, “Bile acid nephropathy in a bodybuilder abusing an anabolic androgenic steroid,” American Journal of Kidney Diseases, vol. 64, no. 3, pp. 473–476, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. S. M. Tabatabaee, R. Elahi, and S. Savoj, “Bile cast nephropathy due to cholestatic jaundice after using stanozolol in 2 amateur bodybuilders,” Iran Journal of Kidney Diseases, vol. 9, pp. 331–334, 2015. View at Google Scholar
  18. Z. M. Szczepiorkowski, N. Bandarenko, H. C. Kim et al., “Guidelines on the use of therapeutic apheresis in clinical practice—Evidence-based approach from the apheresis applications committee of the American society for apheresis,” Journal of Clinical Apheresis, vol. 22, no. 3, pp. 106–175, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. D. D. Ruiz, F. F. San Miguel, F. G. de Molina, A. Úbeda-Iglesias, A. N. Pérez, and R. J. Forés, “Plasmapheresis and other extracorporeal filtration techniques in critical patients,” Medicina Intensiva, vol. 41, no. 3, pp. 174–187, 2017. View at Publisher · View at Google Scholar
  20. P. Krisper, V. Stadlbauer, and R. E. Stauber, “Clearing of toxic substances: are there differences between the available liver support devices?” Liver International, vol. 31, no. 3, pp. 5–8, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Millonig, F. M. Reimann, S. Friedrich et al., “Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis,” Hepatology, vol. 48, no. 5, pp. 1718–1723, 2008. View at Publisher · View at Google Scholar · View at Scopus